Omeros (NASDAQ:OMER) and Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review

Omeros (NASDAQ:OMER) and Guided Therapeutics (OTCMKTS:GTHP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Insider & Institutional Ownership

48.8% of Omeros shares are held by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 66.8% of Guided Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Omeros and Guided Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Guided Therapeutics	N/A	N/A	-274.24%

Analyst Recommendations

This is a summary of recent ratings and target prices for Omeros and Guided Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1	2	2	1	2.50
Guided Therapeutics	0	0	0	0	0.00

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 193.66%. Given Omeros’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Omeros is more favorable than Guided Therapeutics.

Volatility & Risk

Omeros has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Omeros and Guided Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35 million	$0.70	18.49
Guided Therapeutics	$770,000.00	36.36	-$3.20 million	($0.04)	-7.25

Guided Therapeutics has higher revenue and earnings than Omeros. Guided Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Summary

Omeros beats Guided Therapeutics on 9 of the 13 factors compared between the two stocks.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.